SG138488A1 - Novel polypeptides for anti-viral treatment - Google Patents

Novel polypeptides for anti-viral treatment

Info

Publication number
SG138488A1
SG138488A1 SG200604180-0A SG2006041800A SG138488A1 SG 138488 A1 SG138488 A1 SG 138488A1 SG 2006041800 A SG2006041800 A SG 2006041800A SG 138488 A1 SG138488 A1 SG 138488A1
Authority
SG
Singapore
Prior art keywords
novel polypeptides
viral treatment
viral
treatment
polypeptides
Prior art date
Application number
SG200604180-0A
Inventor
Cui Taian
Puah Chum Mok
Liew Oi Wah
Lee Siew Hui
Original Assignee
Singapore Polytechnic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Polytechnic filed Critical Singapore Polytechnic
Priority to SG200604180-0A priority Critical patent/SG138488A1/en
Priority to PCT/SG2007/000168 priority patent/WO2007149052A1/en
Priority to GB0900707A priority patent/GB2453084A/en
Publication of SG138488A1 publication Critical patent/SG138488A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This present invention generally relates to novel polypeptides for use in anti-viral treatment of human diseases.
SG200604180-0A 2006-06-19 2006-06-19 Novel polypeptides for anti-viral treatment SG138488A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SG200604180-0A SG138488A1 (en) 2006-06-19 2006-06-19 Novel polypeptides for anti-viral treatment
PCT/SG2007/000168 WO2007149052A1 (en) 2006-06-19 2007-06-19 Novel polypeptides for anti-viral treatment
GB0900707A GB2453084A (en) 2006-06-19 2007-06-19 Novel polypeptides for an anti-viral treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200604180-0A SG138488A1 (en) 2006-06-19 2006-06-19 Novel polypeptides for anti-viral treatment

Publications (1)

Publication Number Publication Date
SG138488A1 true SG138488A1 (en) 2008-01-28

Family

ID=38833697

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200604180-0A SG138488A1 (en) 2006-06-19 2006-06-19 Novel polypeptides for anti-viral treatment

Country Status (3)

Country Link
GB (1) GB2453084A (en)
SG (1) SG138488A1 (en)
WO (1) WO2007149052A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189653A1 (en) * 2011-12-22 2013-06-27 Medizinische Universitat Wien Cyclotides as immunosuppressive agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
CA2389841A1 (en) * 1999-11-05 2001-05-17 David James Craik Novel nucleic acid molecules encoding cyclised amino acid sequences

Also Published As

Publication number Publication date
GB0900707D0 (en) 2009-03-04
GB2453084A (en) 2009-03-25
WO2007149052A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
MX2009006704A (en) New compounds.
MX2018009945A (en) Novel compositions and methods for the treatment of immune related diseases.
IL186578A0 (en) Compositions for treatment of neovascularization diseases
MX2009006327A (en) Heterocycle compounds and methods of use thereof.
ZA200903862B (en) Nutritional supplement composition for treatment of ocular diseases
HK1129689A1 (en) Targeting complement factor for treatment of diseases
MX356584B (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease.
MX2010005909A (en) Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders.
HK1148684A1 (en) Treatment of prion protein related diseases
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
HK1131047A1 (en) Treatment of inflammatory diseases
IN2012DN03310A (en)
MY164731A (en) Compound
IL190779A0 (en) Compositions for treatment of eye diseases
IN2012DN00971A (en)
EP2004204A4 (en) Treatment of neurodegenerative diseases
SI2056863T1 (en) Treatment of ocular diseases
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism
GB0610183D0 (en) Treatment of neurodegenerative diseases
FI20095600A (en) Composition for the treatment of skin diseases
EP2294197A4 (en) Variant hhip1 protein and methods and uses thereof
GB2458868A8 (en) Treatment of protein aggregation diseases
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
SG138488A1 (en) Novel polypeptides for anti-viral treatment
WO2008037497A3 (en) Galectin-2 for the treatment of inflammatory diseases of the skin